4.7 Review

Recycling the Purpose of Old Drugs to Treat Ovarian Cancer

Journal

Publisher

MDPI
DOI: 10.3390/ijms21207768

Keywords

ovarian cancer; chemoresistance; drug repurposing; ex vivo cultures

Funding

  1. HOPE: Improving ovarian cancer patients' survival-donation from an ovarian cancer patient
  2. FCT (Fundacao para a Ciencia e a Tecnologia) [PTDC/MEC-ONC/29503/2017]
  3. Fundação para a Ciência e a Tecnologia [PTDC/MEC-ONC/29503/2017] Funding Source: FCT

Ask authors/readers for more resources

The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) inhibitors, improved patient survival. However, despite their achievements, ovarian cancer survival remains poor; these therapeutic options are highly costly and can be associated with potential side effects. Recently, it has been shown that the combination of repurposed, conventional, chemotherapeutic drugs could be an alternative, presenting good patient outcomes with few side effects and low costs for healthcare institutions. The main aim of this review is to strengthen the importance of repurposed drugs as therapeutic alternatives, and to propose an in vitro model to assess the therapeutic value. Herein, we compiled the current knowledge on the most promising non-oncological drugs for ovarian cancer treatment, focusing on statins, metformin, bisphosphonates, ivermectin, itraconazole, and ritonavir. We discuss the primary drug use, anticancer mechanisms, and applicability in ovarian cancer. Finally, we propose the use of these therapies to perform drug efficacy tests in ovarian cancer ex vivo cultures. This personalized testing approach could be crucial to validate the existing evidences supporting the use of repurposed drugs for ovarian cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available